AR055179A1 - Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas - Google Patents

Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas

Info

Publication number
AR055179A1
AR055179A1 ARP060104168A ARP060104168A AR055179A1 AR 055179 A1 AR055179 A1 AR 055179A1 AR P060104168 A ARP060104168 A AR P060104168A AR P060104168 A ARP060104168 A AR P060104168A AR 055179 A1 AR055179 A1 AR 055179A1
Authority
AR
Argentina
Prior art keywords
general formula
peptides
seq
formula
compound
Prior art date
Application number
ARP060104168A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR055179A1 publication Critical patent/AR055179A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Un procedimiento para preparar péptidos di- o polibásicos amidados en posicion C-terminal, en el que dos péptidos se hacen reaccionar en presencia de una enzima que tiene la actividad biologica de tripsina, y en caso apropiado el compuesto resultante de la formula (1) se somete a purificacion química de proteínas. Reivindicacion 1: Un procedimiento para preparar péptidos di- o polibásicos amidados en posicion C-terminal de la formula general (1) (AA)n- Xm-NH2 en la que (AA)n es un péptido que consiste en n aminoácidos del mismo o d diferente tipo, en el que AA es un aminoácido o análogos o derivados del mismo; n es un numero entero entre 3 y 2000; y X es un aminoácido de carácter básico o análogos o derivados del mismo; m es un numero entero entre 2 y 15; en la cual un compuesto de la formula general (2), (AA)n-Xp se hace reaccionar con un compuesto de la formula general (3), (X)q-NH2 en la que AA, n y X son como se definen anteriormente, y p y q son numeros enteros, y p + q = m, en presencia de una enzima que tiene la actividad biologica de tripsina, y, en caso apropiado, el compuesto resultante de la formula (1) se somete a purificacion química de proteínas. Reivindicacion 10: Un procedimiento para preparar péptidos di- o polibásicos amidados en posicion C-terminal de la formula general (1) segun una o más de las reivindicaciones 1 a 2, en el que los péptidos de la formula general (1) tienen la actividad biologica de GLP-1 o derivados o análogos del mismo. Reivindicacion 15: Un medicamento que comprende uno o más de los compuestos de la formula (1), caracterizado por las secuencias: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPSKK-NH2 (SEQ ID N° 2); HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPSKR-NH2 (SEQ ID N° 3); HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPSKK KKKR-NH2 (SEQ ID N° 4) o HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPSRK-NH2 (SEQ ID N° 5).
ARP060104168A 2005-09-27 2006-09-25 Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas AR055179A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005046113A DE102005046113A1 (de) 2005-09-27 2005-09-27 Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen

Publications (1)

Publication Number Publication Date
AR055179A1 true AR055179A1 (es) 2007-08-08

Family

ID=37735179

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104168A AR055179A1 (es) 2005-09-27 2006-09-25 Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas

Country Status (20)

Country Link
US (1) US8765910B2 (es)
EP (1) EP1931705B1 (es)
JP (1) JP5352234B2 (es)
KR (1) KR101363299B1 (es)
CN (1) CN101268097A (es)
AR (1) AR055179A1 (es)
AT (1) ATE523522T1 (es)
AU (1) AU2006296818B2 (es)
BR (1) BRPI0616712B8 (es)
CA (1) CA2623547C (es)
CY (1) CY1112182T1 (es)
DE (1) DE102005046113A1 (es)
DK (1) DK1931705T3 (es)
ES (1) ES2373237T3 (es)
IL (1) IL190229A (es)
MY (1) MY148447A (es)
PL (1) PL1931705T3 (es)
PT (1) PT1931705E (es)
SI (1) SI1931705T1 (es)
WO (1) WO2007036299A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
EP2498801B1 (de) 2009-11-13 2018-01-24 Sanofi-Aventis Deutschland GmbH HARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND desPro36Exendin-4(1-39)-Lys6-NH2 UND METHIONIN
CA2786340C (en) 2010-02-11 2017-08-22 F. Hoffmann-La Roche Ag Igf-i poly (ethylene glycol) conjugates
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN108226362B (zh) * 2016-12-21 2021-05-25 鲁南制药集团股份有限公司 一种聚乙二醇化促胰岛素分泌肽类似物中间体的分析检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332664A (en) * 1981-07-15 1994-07-26 Celltech Limited Human calcitonin precursor polyprotein structural gene
US5416073A (en) * 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US5496924A (en) * 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
DK220890D0 (da) * 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
DE69108192T2 (de) * 1990-12-10 1995-07-20 Hoffmann La Roche Verfahren zur enzymatischen Herstellung von GRF(1-44)NH2.
ATE225801T1 (de) * 1992-07-13 2002-10-15 Bionebraska Inc Verfahren zur modifizierung rekombinanter polypeptide
DE19944870A1 (de) * 1999-09-18 2001-03-29 Aventis Pharma Gmbh Signalsequenzen zur Herstellung von Leu-Hirudin über Sekretion durch E. coli in das Kulturmedium
US7638618B2 (en) * 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
EP1546200A2 (en) * 2002-10-02 2005-06-29 Zealand Pharma A/S Stabilized exendin-4 compounds
CA2569707C (en) 2004-08-13 2013-09-24 F. Hoffmann-La Roche Ag C-terminal modification of polypeptides
DE102004058306A1 (de) * 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
EP2229406B1 (de) * 2008-01-09 2015-04-22 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
KR20100111682A (ko) * 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체

Also Published As

Publication number Publication date
JP5352234B2 (ja) 2013-11-27
PL1931705T3 (pl) 2012-02-29
EP1931705B1 (de) 2011-09-07
KR101363299B1 (ko) 2014-02-21
KR20080061367A (ko) 2008-07-02
BRPI0616712B1 (pt) 2018-10-16
PT1931705E (pt) 2011-12-05
WO2007036299A3 (de) 2007-05-31
AU2006296818B2 (en) 2012-03-01
CA2623547A1 (en) 2007-04-05
CN101268097A (zh) 2008-09-17
EP1931705A2 (de) 2008-06-18
CA2623547C (en) 2015-08-11
BRPI0616712A2 (pt) 2011-06-28
ES2373237T3 (es) 2012-02-01
US20100311112A1 (en) 2010-12-09
DE102005046113A1 (de) 2007-03-29
DK1931705T3 (da) 2012-01-09
CY1112182T1 (el) 2015-12-09
ATE523522T1 (de) 2011-09-15
WO2007036299A2 (de) 2007-04-05
IL190229A (en) 2012-12-31
SI1931705T1 (sl) 2011-12-30
MY148447A (en) 2013-04-30
BRPI0616712B8 (pt) 2021-05-25
IL190229A0 (en) 2011-08-01
AU2006296818A1 (en) 2007-04-05
US8765910B2 (en) 2014-07-01
JP2009509515A (ja) 2009-03-12

Similar Documents

Publication Publication Date Title
AR055179A1 (es) Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
EP2573109A3 (en) Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
ATE544775T1 (de) Peptide mit pharmakologischer aktivität zur behandlung von krankheiten die mit veränderter zellmigration assoziiert sind, wie krebs
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
RU2010110564A (ru) Пептид cdca1 и включающее его фармацевтическое средство
RU2016104651A (ru) Устойчивые к протеазам пептидные лиганды
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
RU2012123642A (ru) Аналоги инсулина, содержащие хлорированные аминокислоты
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
ATE509096T1 (de) Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
EP2589658A4 (en) PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN
CN113735937B (zh) 靶向2019新型冠状病毒的木瓜蛋白酶样蛋白酶PLpro的稳定多肽类蛋白共价抑制剂
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
AR110748A1 (es) Proteínas toxinas pesticidas activas contra insectos lepidópteros
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
CN110563802B (zh) 一组含n-甲基化氨基酸及n端脂肪酸修饰的抗菌肽类似物及其合成方法和应用
DE602005025141D1 (de) In Zellen eindringende Peptide als Träger für Moleküle
KR20180016441A (ko) 프로테아제-내성 지질화 glp-1 유사체
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
Stanchev et al. Synthesis of lucifensin by native chemical ligation and characteristics of its isomer having different disulfide bridge pattern
Towle et al. Synthesis and biological studies of neopetrosiamides as inhibitors of cancer cell invasion

Legal Events

Date Code Title Description
FG Grant, registration